On the basis of parallel in vitro studies with antibiotic G-418, gentamicin, neomycin, and kanamycin, antibiotic G-418 was found to be less potent than gentamicin but more active than either kanamycin or neomycin against most stre ins, with the exception of Pseudomonas, for which neomycin was more active than antibiotic G-418, and enterococci, for which antibiotic G-418 was more active than the other three antibiotics. Mouse protection tests indicated that antibiotic G-418 is approximately half as potent as gentamicin and its acute toxicity is one-half to one-third that of gentamicin.
Antibiotic G-418 is a novel aminoglycoside produced by a new species of Micromonospora, M. rhodorangea. Wagman and co-workers (1) have described the isolation and characterization of antibiotic G-418, as well as the taxonomy of the producing culture. Antibiotic G-418 is of interest not only because of its antibacterial activity but also because of its activity against a variety of protozoa and helminths. The antiparasitic activity of G-418 will be described elsewhere. This paper is concerned with the antibacterial aspects of antibiotic G-418.
MATERIALS AND METHODS
Bacterial strains used were from a standard collection of recent clinical isolates and represent a variety of gram-negative and gram-positive bacteria. In addition, a collection of 58 Escherichia coli strains, provided by Howard Bachmann, Schering Animal Health Division, had been isolated from a variety of diseases throughout the United States which were of importance to the Animal Health Division. Minimal inhibitory concentrations were done using an agar dilution procedure with two-fold dilutions based on 1 Ag/ml. For these studies, Mueller-Hinton agar was used with an inoculum of 104 bacterial cells. Plates were inoculated using a Steers-Foltz replicating device. For all in vitro tests, gentamicin, neomycin, and kanamycin were included as reference antibiotics and were tested in parallel with antibiotic G-418. In vivo efficacy and toxicity tests were done in male CF1 mice weighing approximately 20 g each, as described earlier (2). For determination of efficacy, mean protective dose values in terms of milligrams per kilogram were determined on the basis of treatment groups of seven mice each at five to seven dose levels and a control group of 10 mice. The mice were given a single subcutaneous dose of drug 1 h after intraperitoneal infection with approximately 107 organisms per mouse. Infections routinely produced death in untreated infected controls in 18 to 24 h. Mean protective dose values were determined using probit procedures based on survivors 48 h after infection. All antibiotics were used as the sulfate salts; results are given in terms of base activity.
RESULTS AND DISCUSSION
Results of agar dilution minimal inhibitory concentration tests are shown in Table 1 for antibiotic G-418 in parallel with gentamicin, neomycin, and kanamycin. The results are presented in terms of cumulative percent inhibited by various concentrations for each of the bacterial species. For most of the strains tested, including the E. coli isolates from a variety of animal diseases, antibiotic G-418 was not as potent as gentamicin; it was, however, more active than either neomycin or kanamycin. Exceptions to this general pattern were noted with Pseudomonas aeruginosa. In Table 1 these are divided into 45 gentamicin-sensitive Pseudomonas strains, in addition to these strains plus 10 gentamicin-resistant strains. For both groups of Pseudomonas, neomycin was more active than antibiotic G-418. Another exception to the general trend was in the case of enterococci, for which antibiotic G-418 was more active than any of the other three antibiotics. Table 2 . Mean protective dose values, as well as the ratio of activity calculated for each infection by dividing the mean protective dose of antibiotic G-418 by that of gentamicin, are shown for both of the antibiotics. In these ratios, the higher the number, the less potent, relatively, was antibiotic G-418. The ratios range from 0.9 to 4.8 with an average slightly less than 2, indicating that in mouse protection tests it took approximately twice as much antibiotic G-418 as gentamicin to protect mice from death. Results of acute intravenous or subcutaneous toxicity tests in mice are shown in Table 3 . Antibiotic G-418 was found to be approximately one-half to one-third as toxic as gentamicin. 
